The PI3Kδ Inhibitor Idelalisib Inhibits Homing in an in Vitro and in Vivo Model of B ALL-Reference-Cited by-同舟云学术

The PI3Kδ Inhibitor Idelalisib Inhibits Homing in an in Vitro and in Vivo Model of B ALL

Published:2017-09-10 Issue:12 Volume:9 Page:121
ISSN:2072-6694
Container-title:Cancers
language:en
Short-container-title:Cancers

Author:

Adam Etai,Kim Hye Na,Gang Eun Ji,Schnair Caitlin,Lee Solomon,Lee Solah,Khazal Sajad,Kosoyan Osanna,Konopleva Marina,Parekh Chintan,Bhojwani Deepa,Wayne Alan S.,Abdel-Azim Hisham,Heisterkamp Nora,Kim Yong-Mi

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Link

http://www.mdpi.com/2072-6694/9/9/121/pdf

Reference25 articles.

1. Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group

2. Relapsed childhood acute lymphoblastic leukaemia

3. Role of Integrin Alpha4 in Drug Resistance of Leukemia

4. The phosphatidylinositol 3-Kinase–AKT pathway in human cancer

5. p110δ, a Novel Phosphatidylinositol 3-Kinase Catalytic Subunit That Associates with p85 and Is Expressed Predominantly in Leukocytes

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Total flavonoids of Litchi chinensis Sonn. seed inhibit prostate cancer growth in bone by regulating the bone microenvironment via inactivation of the HGFR/NF-κB signaling pathway;Journal of Ethnopharmacology;2024-01

2. Obesity and Leukemia: Biological Mechanisms, Perspectives, and Challenges;Current Obesity Reports;2023-12-30

3. In the Pipeline—Emerging Therapy for ALL;Pathogenesis and Treatment of Leukemia;2023

4. PI3K Targeting in Non-solid Cancer;Current Topics in Microbiology and Immunology;2022

5. Preclinical Evaluation of a Novel Dual Targeting PI3Kδ/BRD4 Inhibitor, SF2535, in B-Cell Acute Lymphoblastic Leukemia;Frontiers in Oncology;2021-12-01